Isoprinosine in HIV Patients With Viral Load > 50 y < 200 Copies/mL
Status:
Active, not recruiting
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
Virological failure is a complication of treatment in patients with HIV, and it can be as
high as 42% to first line treatment or around 18% in second line treatment. The reasons
behind this phenomenon are several, including adherence to treatment (self-patient) or those
related to the drugs (kinetics, interactions) and the virus itself (resistance patterns).
People living with HIV needs treatment for all their lives, another factor to facilitate
virus resistance and poor adherence to treatment. For that reason, it is necessary to look
for additional therapeutic options to minimize this problem, and the use of immunomodulatory
drugs is an interesting topic now. Among those drugs, isoprinosine hs been reported not only
improve the immune response, it also has the capability to inhibit the replication of RNA
virus. Then, we propose an open label clinical trial to evaluate the effect of isoprinosine
in HIV patients with a virological load between 50 and 200 copies/ml.